Sugi Predict

Sugi Predict / Compounds / SCHEMBL5266910

SCHEMBL5266910

SCHEMBL5266910

Cc1oc2cc(O)ccc2c(=O)c1-c1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 10/20 1.00
▸ KDM4E B2RXH2 10/20 1.00
▸ HPGD P15428 6/20 0.71
▸ HSD17B10 Q99714 6/20 0.71
▸ GAA P10253 4/20 0.71
▸ TP53 P04637 2/20 0.71
▸ MAPT P10636 5/20 0.67
▸ CYP2C19 P33261 3/20 0.67
▸ CYP3A4 P08684 3/20 0.67
▸ CYP1A2 P05177 2/20 0.67
▸ CYP2C9 P11712 2/20 0.67
▸ TSHR P16473 2/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ ERAP1 Q9NZ08 1/20 0.66
▸ GLA P06280 3/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ PKM P14618 2/20 0.61
▸ KEAP1 Q14145 1/20 0.61
▸ NFE2L2 Q16236 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5990563 0.88 ALDH1A1 (0.78) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL12722331 0.87 ALDH1A1 (0.77) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL2332295 0.86 ALDH1A1 (0.76) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL14185243 0.86 ALDH1A1 (0.75) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL5315268 0.86 ALDH1A1 (0.75) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL27717859 0.85 KDM4E (0.74) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL7948035 0.84 MEN1 (0.76) ALDH1A1KDM4EHPGDHSD17B10TP53
SCHEMBL2946452 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL30991582 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10GAA
SCHEMBL10815394 0.83 ALDH1A1 (0.71) ALDH1A1KDM4EHPGDHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109400568-A 7- aroyl acetyl oxygroup isoflavone derivative and its application on pesticide 江苏大学 2019-03-01 — — CN disclosed
CN-107349309-A A kind of compound bavin head red sage root anti-liver cancer and anti-oral liquids and its preparation technology 冯敏杰 2017-11-17 — — CN disclosed
CN-105311046-A Composition for antiwrinkle, antiinflammatory and skin-whitening effect comprising liquiritin apioside COTDE INC 2016-02-10 — — CN disclosed
CN-104861015-A Synergistic clean extraction method of effective components in licorice root LI YUSHAN 2015-08-26 — — CN disclosed
CN-101948475-B Isoflavone derivate-chromene (chroman) oxazines compound, preparation method and application thereof UNIV SHENYANG PHARMACEUTICAL 2014-06-25 — — CN disclosed
CN-101948475-A Isoflavone derivate-chromene (chroman) oxazines compound, preparation method and application thereof UNIV SHENYANG PHARMACEUTICAL 2011-01-19 — — CN disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
EP-1456180-B1 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE VERNALIS CAMBRIDGE LTD (GB) 2007-10-03 — — EP disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-7247734-B2 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2007-07-24 — — US disclosed
US-20060251741-A1 Stable, homogeneous natural product extracts containing polar and apolar fractions AUST DUNCAN T 2006-11-09 — — US disclosed
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer VERNALIS (CAMBRIDGE) LIMITED (GB) 2005-10-06 — — US disclosed
EP-1456180-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER Vernalis (Oxford) Ltd (GB) 2004-09-15 — — EP disclosed
WO-2003055860-A1 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER VERNALIS (CAMBRIDGE) LIMITED (GB) 2003-07-10 — — WO disclosed
US-20030026856-A1 Stable, homogeneous natural product extracts containing polar and apolar fractions COLLABORATIVE TECHNOLOGIES, INC. 2003-02-06 — — US disclosed
US-6485756-B1 TO COMBINE BOTH THE POLAR AND APOLAR EXTRACTS INTO A SINGLE, HOMOGENEOUS PREPARATION WITHOUT THE USE OF SURFACE ACTIVE AGENTS WHICH CAN CAUSE IRRITATION; PHOSPHOLIPIDS MAY BE USED TO ACHIEVE SURFACTANT-FREE DISPERSIONS COLLABORATIVE TECHNOLOGIES, INC. 2002-11-26 — — US disclosed
US-4166862-A WEIGHT-GAIN PROMOTERS CHINOIN GYOGYSZER ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1979-09-04 — — US disclosed
US-3949085-A Anabolic-weight-gain promoting compositions containing isoflavone derivatives and method using same CHINOIN GYOGYSZER-ES VEGYESZETI TERMAKEK GYARA RT (HU) 1976-04-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060251741-A1 Stable, homogeneous natural product extracts containing polar and apolar fractions PLTP, PHOSPHO1, APOB ALDH1A1 4603/4885KDM4E 4820/4885HPGD 1013/4885
US-20050222230-A1 3,4-diarylpyrazoles and their use in the therapy of cancer HSP90AB1, HSP90AA1, HSP90AB2P ALDH1A1 986/4885KDM4E 1999/4885HPGD 383/4885
US-20030026856-A1 Stable, homogeneous natural product extracts containing polar and apolar fractions PLTP, PHOSPHO1, APOB ALDH1A1 4603/4885KDM4E 4820/4885HPGD 1013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.